You can buy Luciselade at the lowest price in the online pharmacy Nextgen.ooo . Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis, which is a condition associated with aberrant bile acid metabolism. Seladelpar works to block bile acid synthesis. Seladelpar is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. Use of seladelpar is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).
 
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor superfamily with three members - PPAR-alpha (α), PPAR-delta (δ), and PPAR-gamma (γ). Each PPAR plays a role in maintaining energy homeostasis and metabolic function, such as fatty acid metabolism, bile acid synthesis, and adipocyte differentiation. In chronic liver disorders such as PBC and nonalcoholic steatohepatitis (NASH), changes in bile acid composition and increased systemic bile acids are observed.